Natera Unveils New Signatera Data Showing Superior Lymphoma Recurrence Detection at ASH 2025
Natera Inc. will present new data on its Signatera™ test at the 2025 ASH Annual Meeting, highlighting its superior detection of lymphoma recurrence. Signatera outperformed standard methods, detected recurrence before imaging, and clarified ambiguous imaging results. It also serves as a response assessment tool, with ctDNA-measurable residual disease included in NCCN Guidelines for diffuse large B-cell lymphoma. The findings will be shared in oral and poster sessions.
Natera Inc. has announced that new data on its Signatera™ test will be presented at the 2025 American Society of Hematology (ASH) Annual Meeting, scheduled for December 6-9, 2025, in Orlando, Florida. The presentations will highlight the clinical validity and utility of Signatera in hematologic malignancies, including aggressive and indolent lymphomas and multiple myeloma. Key findings to be presented suggest that Signatera detected recurrence prior to imaging and outperformed standard surveillance methods. Additionally, personalized circulating tumor DNA (ctDNA) detection was found to be a strong predictor of clinical outcomes, and Signatera helped clarify ambiguous imaging results. The data also support the use of Signatera as a response assessment tool in lymphoma, and ctDNA-measurable residual disease was incorporated into the NCCN Guidelines for diffuse large B-cell lymphoma in January 2025. The results will be presented in oral and poster sessions during the meeting. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251203828324) on December 03, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
